Realm Therapeutics PLC Director/PDMR Shareholding (4271Z)

TIDMRLM

RNS Number : 4271Z

Realm Therapeutics PLC

15 December 2017

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

Grant of Options

15 December 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces the grant of 2,080,000 share options to its directors and senior management to subscribe for ordinary shares of 10p each in the capital of the Company (the "Options"), as detailed below. All Options were granted on 13 December 2017 (the "Grant Date"), have an exercise price of 38.5 pence each and a ten-year term.

Grants to Executive Directors vest one-third per year on each of the first three anniversaries of the Grant Date on the basis of attainment of certain key performance measures relating to clinical development and other strategic targets, which will be evaluated on the relevant anniversaries. Grants to the Chief Medical Officer and Non-Executive Directors vest one-third per year on each of the first three anniversaries of the Grant Date.

Grants made to Executive Directors under the Realm Therapeutics plc Executive Omnibus Incentive Plan 2016 (the "Plan") are noted below.

 
 Name                                Number of Options 
                                          Granted 
 Alex Martin (Chief Executive 
  Officer)                                830,000 
 Marella Thorell (Chief Financial 
  & Operating Officer)                    350,000 
 
 

In addition, Christian Peters (Chief Medical Officer) has been granted 350,000 options.

Grants made to Non-Executive Directors, under individual agreements which are subject to the provisions of the Plan, are noted below. Mr. Zweifach's grant relates to his initial appointment to the Board.

 
 Name                                       Number of Options 
                                                 Granted 
 Charles Spicer (Non-Executive 
  Chairman)                                      100,000 
 William Birkett (Senior Independent 
  Non-Executive Director)                        100,000 
 Balkrishan (Simba) Gill (Non-Executive 
  Director)                                      100,000 
 Ivan Gergel (Non-Executive Director)            100,000 
 Sanford (Sandy) Zweifach (Non-Executive 
  Director)                                      150,000 
 

Following the above grants there is a total of approximately 11.4 million options over ordinary shares outstanding which represents approximately 9.8% of the current issued share capital of the Company.

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: [phone]

US: [phone]

Argot Partners

Stephanie Marks

[phone]

FTI Consulting

Simon Conway / Mo Noonan

[phone]

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer

[phone]

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.

Additional Disclosure

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
        with them 
----  ------------------------------------------------------------------- 
 a)    Name                                    1. Alex Martin 
                                                2. Marella Thorell 
                                                3. Christian Peters 
                                                4. Sanford (Sandy) 
                                                Zweifach 
                                                5. Charles Spicer 
                                                6. William Birkett 
                                                7. Balkrishan (Simba) 
                                                Gill 
                                                8. Ivan Gergel 
----  ---------------------------------  -------------------------------- 
 2     Reason for notification 
----  ------------------------------------------------------------------- 
 a)    Position/status                         1. Chief Executive 
                                                Officer 
                                                2. Chief Financial 
                                                & Operating Officer 
                                                3. Chief Medical 
                                                Officer 
                                                4. Non-Executive 
                                                Director 
                                                5. Non-Executive 
                                                Chairman 
                                                6. Senior Independent 
                                                Non-Executive Director 
                                                7. Non-Executive 
                                                Director 
                                                8. Non-Executive 
                                                Director 
----  ---------------------------------  -------------------------------- 
 b)    Initial notification/Amendment     Initial Notification 
----  ---------------------------------  -------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
----  ------------------------------------------------------------------- 
 a)    Name                               Realm Therapeutics 
                                           PLC 
----  ---------------------------------  -------------------------------- 
 b)    LEI                                n/a 
----  ---------------------------------  -------------------------------- 
 4     Details of the transaction(s): section to 
        be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
----  ------------------------------------------------------------------- 
 a)    Description of the financial       Ordinary shares 
        instrument, type of instrument     in Realm Therapeutics 
        Identification code                PLC 
                                           ISIN: GB00B3XBCR18 
----  ---------------------------------  -------------------------------- 
 b)    Nature of transaction              Grant of options 
                                           over 2,080,000 shares 
                                           under the Realm 
                                           Therapeutics plc 
                                           Executive Omnibus 
                                           Incentive Plan 2016 
                                           and individual agreements 
----  ---------------------------------  -------------------------------- 
 c)    Price(s) and volume(s)             Price(s)          Volume(s) 
----  ---------------------------------  ----------------  -------------- 
   1. 38.50                                                 830,000 
    pence 
 
    2. 38.50 
    pence                                                    350,000 
 
    3. 38.50                                                 350,000 
    pence 
 
    4. 38.50 
    pence                                                    150,000 
 
    5. 38.50 
    pence                                                    100,000 
 
    6. 38.50 
    pence                                                    100,000 
 
    7. 38.50 
    pence                                                    100,000 
 
    8. 38.50 
    pence                                                    100,000 
  -------------------------------------------------------  -------------- 
 d)         Aggregated information        n/a 
              *    Aggregated volume       (Single transaction 
                                           for each recipient 
                                           of options) 
              *    Price 
----  ---------------------------------  -------------------------------- 
 e)    Date of the transaction            13 December 2017 
----  ---------------------------------  -------------------------------- 
 f)    Place of the transaction           Outside a trading 
                                           venue 
----  ---------------------------------  -------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFLDFILSLID

(END) Dow Jones Newswires

December 15, 2017 02:00 ET (07:00 GMT)